Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 2Melanoma 2Carcinoma, Non-Small-Cell Lung 2Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Locally Advanced Colorectal Cancer 1Hodgkin Disease 1Gastric Adenocarcinoma 1Colorectal Cancer Metastatic 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Gastric Cancer 1

Interventions

Gastrectomy 4Taxes 3sintilimab 2S 1 (combination) 2Paclitaxel 2Oxaliplatin 2Hyperthermic Intraperitoneal Chemotherapy 2Drug Therapy 2Cisplatin 2Albumin-Bound Paclitaxel 2trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tipiracil 1taxane 1pembrolizumab 1durvalumab 1disitamab vedotin 1cabozantinib 1apatinib 1XELOX 1Trifluridine 1Tegafur 1Tadalafil 1SHR-1701 1Resistance Training 1Radiotherapy 1Platinum 1Magnetic Resonance Spectroscopy 1Irinotecan 1Indocyanine Green 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gastric Adenocarcinoma × SHR-1701 × Clear all
NCT07464756 2026-03-11

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
80 enrolled
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡